Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23777360 | 1.00 | HDAC1 (0.51) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL19463712 | 0.91 | NAALAD2 (0.50) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL29329450 | 0.91 | NAALAD2 (0.50) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL19464087 | 0.91 | NAALAD2 (0.50) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13750377 | 0.84 | MMP2 (0.51) | MAPTTDP1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL16689718 | 0.82 | JAK3 (0.47) | ALDH1A1L3MBTL1MAPTTDP1LMNA | |
| SCHEMBL10192653 | 0.82 | KMT2A (0.51) | NR4A2GAAALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL10192637 | 0.82 | KMT2A (0.51) | NR4A2GAAALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL10192651 | 0.82 | KMT2A (0.51) | NR4A2GAAALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL14750389 | 0.82 | DPP4 (0.45) | NR4A2ALDH1A1CYP2C19L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-13 | — | — | US | disclosed |
| US-20230110295-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3950004-A1 | TARGETED COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20200407724-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-12-31 | — | — | US | disclosed |
| EP-3610017-A2 | TARGETED COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2020-02-19 | — | — | EP | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| EP-3443092-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2019-02-20 | — | — | EP | disclosed |
| WO-2018191278-A2 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-10-18 | — | — | WO | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | HDAC1 4442/4885HDAC3 3936/4885HDAC4 4016/4885 |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | HAVCR2, DCTD, POLRMT | HDAC1 4442/4885HDAC3 3936/4885HDAC4 4016/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | HDAC1 2914/4885HDAC3 1400/4885HDAC4 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.